GO:0050660 flavin adenine dinucleotide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050660 flavin adenine dinucleotide binding describes the molecular function of binding FAD or FADH2, the oxidized and reduced forms of the flavin coenzyme.
• FAD binding is essential for oxidoreductase enzymes, flavoproteins, and diverse cellular processes including redox reactions, DNA repair, and circadian rhythms.
• Key genes encoding FAD-binding proteins include FLAD1, GDH, SOX9, CRY1, CRY2, and molybdenum-containing carbon monoxide dehydrogenase.
• Defects in FAD binding or FAD homeostasis are linked to metabolic disorders, cancer, and neurodegenerative conditions such as Friedreich ataxia.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of FAD-binding protein function in health and disease.
• Studying FAD binding requires integrated methods including structural biology, enzymology, biosensing, and CRISPR-based screens.
Description
Flavin adenine dinucleotide (FAD) is a redox-active coenzyme that serves as a prosthetic group for numerous flavoproteins. The Gene Ontology term GO:0050660, flavin adenine dinucleotide binding, defines the molecular function of selectively interacting with FAD or its reduced form FADH2. This binding event is fundamental to electron transfer, oxidation-reduction reactions, and a wide array of metabolic and regulatory pathways. FAD binding proteins are found across all kingdoms of life, from bacteria to humans, and their dysfunction is associated with severe pathologies. Understanding the structural and functional basis of FAD binding is therefore critical for both basic biology and therapeutic development. Recent studies have elucidated the structural determinants of FAD binding in cryptochromes, the role of FAD in pancreatic progenitor transcription factor regulation, and the biotechnological applications of FAD-dependent enzymes. This article synthesizes current knowledge on GO:0050660, covering its definition, mechanism, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based approaches for functional interrogation.
flavin adenine dinucleotide binding At A Glance
| GO ID | GO:0050660 |
|---|---|
| GO term | flavin adenine dinucleotide binding |
| Ontology | molecular_function |
| Synonym | FAD or FADH2 binding; flavine-adenine dinucleotide binding |
| Major function | Binding of FAD/FADH2 coenzyme or prosthetic group to flavoproteins |
| Definition source | QuickGO |
| Related cofactor | Flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN) |
| Representative proteins | Cryptochrome, glucose dehydrogenase, Sox9, FAD synthase, carbon monoxide dehydrogenase |
| Disease relevance | Friedreich ataxia, metabolic disorders, cancer, circadian rhythm disruption |
What Is GO:0050660?
GO:0050660 flavin adenine dinucleotide binding is defined as the binding to FAD, flavin-adenine dinucleotide, the coenzyme or prosthetic group of various flavoprotein oxidoreductase enzymes, in either the oxidized form FAD or the reduced form FADH2. This molecular function encompasses non-covalent and covalent interactions that anchor the flavin isoalloxazine ring within a protein binding pocket, enabling electron transfer and catalysis.
Why Is flavin adenine dinucleotide binding Important in Cell Biology?
FAD binding is indispensable for the catalytic activity of hundreds of flavoenzymes that participate in energy metabolism, oxidative stress response, DNA repair, and circadian regulation. Disruption of FAD binding can lead to loss of enzyme function, accumulation of toxic metabolites, and disease. For example, FAD rescues the phenotype of frataxin deficiency, highlighting its therapeutic potential in Friedreich ataxia. Moreover, FAD-dependent enzymes such as glucose dehydrogenase are exploited in biosensors and biofuel cells. Thus, understanding GO:0050660 is central to both fundamental biochemistry and translational research.
• FAD binding enables electron transfer in oxidoreductases, critical for cellular respiration and metabolism.
• Mutations in FAD-binding domains cause enzyme deficiencies linked to metabolic diseases.
• FAD binding to cryptochromes regulates circadian rhythms and magnetoreception.
• FAD-dependent glucose dehydrogenase is used in continuous glucose monitoring biosensors.
• FAD binding to Sox9 modulates pancreatic progenitor transcription factor expression.
• FAD supplementation rescues frataxin deficiency phenotypes, suggesting therapeutic avenues.
• Bacterial FAD synthases are potential antibiotic targets.
• FAD binding is essential for styrene monooxygenase activity in bioremediation.
• Structural studies of FAD binding inform drug design and protein engineering.
• CRISPR screens targeting FAD-binding genes can uncover novel disease mechanisms.
What Happens During flavin adenine dinucleotide binding?
Recognition and Initial Docking of FAD
In simple terms: The protein first recognizes and loosely grabs the FAD molecule.
FAD binding begins with the specific recognition of the flavin adenine dinucleotide molecule by a conserved binding pocket within the target protein. Structural studies of Drosophila melanogaster cryptochrome reveal that key aromatic residues and hydrogen-bonding networks position the isoalloxazine ring for optimal stacking and electron transfer. In molybdenum-containing carbon monoxide dehydrogenase, the recombinant flavoprotein replaces the native counterpart, demonstrating the importance of precise docking for catalytic activity. The binding is typically non-covalent but can involve covalent attachment in some flavoproteins.
Conformational Changes and Stabilization
In simple terms: The protein changes shape to lock the FAD in place.
Upon FAD binding, many flavoproteins undergo conformational changes that stabilize the coenzyme and prime the active site. For example, FAD binding to Sox9 alters its interaction with pancreatic progenitor transcription factors, indicating that FAD can modulate protein-protein interactions beyond redox chemistry. In Escherichia coli pyruvate oxidase, studies of the FAD binding region highlight specific residues that contribute to tight binding and catalytic competence. These conformational dynamics are often essential for enzyme activation.
Electron Transfer and Catalysis
In simple terms: Once bound, FAD helps move electrons to drive chemical reactions.
The bound FAD/FADH2 participates in electron transfer chains, accepting and donating electrons in oxidoreductase reactions. Styrene monooxygenase utilizes FAD to epoxidize styrene, a key step in bioremediation. FAD-dependent glucose dehydrogenase transfers electrons from glucose to electrodes in biosensors, demonstrating efficient electron transfer. The redox state of FAD is tightly controlled to prevent unwanted side reactions.
Regulation and Recycling of FAD
In simple terms: Cells control how much FAD is available and recycle it after use.
FAD homeostasis is regulated by biosynthesis, salvage, and degradation pathways. The FAD synthase from Brucella ovis catalyzes the final step of FAD biosynthesis from FMN, and its activity is essential for pathogen survival. In humans, FAD levels can be modulated by dietary riboflavin and are implicated in disease; FAD supplementation rescues frataxin deficiency phenotypes. Thus, FAD binding is dynamically regulated at the level of cofactor availability.
Key Genes Involved in GO:0050660 flavin adenine dinucleotide binding
The following genes encode proteins that bind FAD or regulate its availability, representing key players in GO:0050660.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FLAD1 | FAD synthase; catalyzes FAD biosynthesis from FMN | Target for antibacterial development; mutations cause metabolic disorders |
| GDH | FAD-dependent glucose dehydrogenase; oxidizes glucose | Biosensor and biofuel cell applications |
| SOX9 | Transcription factor; binds FAD to modulate pancreatic progenitor genes | Pancreatic development and diabetes research |
| CRY1 | Cryptochrome; FAD-binding photoreceptor | Circadian rhythm and magnetoreception studies |
| CRY2 | Cryptochrome; FAD-binding photoreceptor | Circadian rhythm regulation |
| COX | Carbon monoxide dehydrogenase; FAD-containing oxidoreductase | Bacterial CO metabolism and bioremediation |
| PYRUVATE_OXIDASE | E. coli pyruvate oxidase; FAD-dependent decarboxylase | Model for FAD binding region studies |
| STYRENE_MONOOXYGENASE | FAD-dependent epoxidase | Bioremediation of styrene |
| FXN | Frataxin; involved in iron-sulfur cluster biogenesis; FAD rescues deficiency | Friedreich ataxia therapy |
| ETFA | Electron transfer flavoprotein alpha subunit; FAD-binding | Fatty acid oxidation and metabolic disorders |
| ETFB | Electron transfer flavoprotein beta subunit; FAD-binding | Glutaric acidemia type II |
| ACADM | Medium-chain acyl-CoA dehydrogenase; FAD-dependent | Fatty acid oxidation defects |
| SDHA | Succinate dehydrogenase complex flavoprotein subunit A | Mitochondrial respiration and cancer |
| SDHB | Succinate dehydrogenase complex iron sulfur subunit B | Paraganglioma and pheochromocytoma |
| MTHFR | Methylenetetrahydrofolate reductase; FAD-dependent | Folate metabolism and cardiovascular disease |
| NOS2 | Inducible nitric oxide synthase; FAD-binding | Inflammation and cancer |
| POR | Cytochrome P450 oxidoreductase; FAD/FMN-binding | Drug metabolism and steroidogenesis |
| DUOX2 | Dual oxidase 2; FAD-dependent | Thyroid hormone synthesis and innate immunity |
How Is flavin adenine dinucleotide binding Regulated?
FAD binding and FAD-dependent processes are regulated at multiple levels. Cellular FAD levels are controlled by the riboflavin transporter SLC52A1-3, FAD synthase (FLAD1), and FAD pyrophosphatase. Transcriptional regulation of FAD-binding proteins responds to metabolic cues; for instance, Sox9 binding to FAD alters expression of pancreatic progenitor transcription factors. Post-translational modifications and redox state can modulate FAD binding affinity. In pathogens, FAD biosynthesis is essential and is being explored as an antibiotic target. Additionally, FAD supplementation can bypass genetic defects in FAD binding, as shown in frataxin deficiency.
flavin adenine dinucleotide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FXN | Friedreich ataxia | Knockout or knockdown in neurons; FAD rescue |
| FLAD1 | Multiple acyl-CoA dehydrogenase deficiency | Point mutation knock-in in cell lines |
| CRY1/CRY2 | Circadian rhythm sleep disorders, cancer | Knockout mice; circadian behavioral assays |
| SDHA/SDHB | Paraganglioma, pheochromocytoma | Knockout in chromaffin cells; metabolic profiling |
| GDH | Diabetes monitoring | Overexpression in yeast for biosensor development |
Friedreich Ataxia and Mitochondrial Dysfunction
Friedreich ataxia is caused by reduced frataxin levels, leading to mitochondrial iron overload and oxidative stress. FAD supplementation rescues the phenotype of frataxin deficiency in cellular and animal models, suggesting that enhancing FAD binding or availability can compensate for mitochondrial dysfunction. This highlights the therapeutic potential of targeting FAD-dependent pathways.
Metabolic Disorders and FAD Synthase Deficiency
Mutations in FLAD1, the FAD synthase, cause a rare metabolic disorder characterized by multiple acyl-CoA dehydrogenase deficiency (MADD). Impaired FAD synthesis reduces FAD binding to dehydrogenases, disrupting fatty acid oxidation and energy production. This underscores the importance of FAD homeostasis in metabolic health.
Cancer and Circadian Disruption
Cryptochromes (CRY1/CRY2) are FAD-binding proteins that regulate circadian rhythms. Disruption of circadian rhythms is associated with increased cancer risk. Structural studies of Drosophila cryptochrome provide insights into FAD binding mechanisms that could inform cancer chronotherapy. Additionally, succinate dehydrogenase (SDHA/SDHB) mutations, which affect FAD binding, are linked to hereditary paraganglioma and pheochromocytoma.
Infectious Diseases and Antibacterial Targets
The FAD synthase from Brucella ovis is essential for pathogen survival, making it a potential antibacterial target. Inhibiting FAD binding or biosynthesis could cripple bacterial metabolism and virulence. This approach is particularly attractive for drug-resistant pathogens.
From flavin adenine dinucleotide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FAD binding abolish enzyme activity? | CRISPR knockout of FAD-binding domain |
| How does a disease-associated point mutation affect FAD affinity? | CRISPR point mutation knock-in |
| Can a tagged FAD-binding protein be used for localization studies? | Knock-in of fluorescent tag (e.g., GFP) |
| Does overexpression of FAD synthase increase FAD levels? | CRISPR overexpression (CRISPRa) or cDNA overexpression |
| Which genes are essential for FAD homeostasis? | Genome-wide CRISPR library screening |
| What is the structural basis of FAD binding? | X-ray crystallography or cryo-EM of purified protein |
How to Study the flavin adenine dinucleotide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of FAD-protein complex | Elucidating binding mode |
| Isothermal titration calorimetry (ITC) | Binding affinity (Kd) of FAD to protein | Quantifying mutant effects |
| Enzyme activity assay | Catalytic rate of FAD-dependent enzyme | Functional characterization |
| Electrochemical biosensor | Electron transfer from FAD enzyme to electrode | Glucose monitoring |
| CRISPR knockout screening | Gene essentiality and fitness | Identifying FAD pathway genes |
| Metabolomics (LC-MS) | FAD, FADH2, and related metabolites | Assessing cellular FAD status |
| Circadian behavioral assay | Rhythmic activity in model organisms | Cryptochrome function |
Structural Biology (X-ray Crystallography and Cryo-EM)
Determining the atomic structure of FAD-protein complexes reveals the precise binding interactions. For example, structural explanations of FAD binding in Drosophila cryptochrome were obtained using crystallography. These methods guide mutagenesis and drug design.
Enzymatic Assays and Biosensors
FAD-dependent enzyme activity can be measured using spectrophotometric assays that monitor NADH or FADH2 production. Electrochemical biosensors using FAD-dependent glucose dehydrogenase enable sensitive glucose detection. These assays quantify the functional consequences of FAD binding.
CRISPR-Based Functional Genomics
CRISPR knockout, point mutation, and overexpression screens can systematically test the role of FAD-binding proteins in cellular processes. For instance, knocking out FLAD1 would impair FAD synthesis and reveal downstream effects. Such screens are powerful for identifying disease modifiers.
Metabolomics and Flux Analysis
Mass spectrometry-based metabolomics can measure FAD and FADH2 levels, as well as metabolites from FAD-dependent pathways. This approach has been used to study the metabolic impact of FAD supplementation in frataxin deficiency.
How CRISPR Can Be Used to Study GO:0050660 flavin adenine dinucleotide binding
Knockout
CRISPR knockout of genes encoding FAD-binding proteins (e.g., FLAD1, GDH, CRY1) can abolish protein function and reveal loss-of-function phenotypes. For example, knocking out FLAD1 would disrupt FAD synthesis, leading to impaired fatty acid oxidation. Knockout models are essential for validating gene essentiality.
Point Mutation
Introducing disease-associated point mutations into FAD-binding domains (e.g., in SDHA or FXN) via CRISPR base editing or HDR allows precise assessment of how single amino acid changes affect FAD binding affinity and enzyme activity. This approach mimics human genetic variants.
Knock-in
Knock-in of tags (e.g., GFP, HA) or reporter genes into endogenous FAD-binding protein loci enables real-time tracking of protein localization and expression. For instance, tagging cryptochrome with a fluorescent protein can reveal its nuclear-cytoplasmic shuttling in circadian regulation.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase levels of FAD-binding proteins or FAD synthases, allowing gain-of-function studies. Overexpressing FAD synthase may elevate cellular FAD levels and rescue metabolic defects. This is useful for testing therapeutic hypotheses.
How EDITGENE Supports flavin adenine dinucleotide binding Research
Researchers studying flavin adenine dinucleotide binding-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, and CRISPR-based models provide the most direct route to that answer. EDITGENE offers a comprehensive suite of services to generate precisely engineered cell lines and libraries for FAD biology.
Contact EDITGENE today to design your custom CRISPR model for flavin adenine dinucleotide binding research.
Frequently Asked Questions About flavin adenine dinucleotide binding
What is flavin adenine dinucleotide binding?
Flavin adenine dinucleotide binding (GO:0050660) is the molecular function of binding to FAD or FADH2, the oxidized and reduced forms of the flavin coenzyme, typically by flavoproteins.
What genes are involved in flavin adenine dinucleotide binding?
Key genes include FLAD1 (FAD synthase), GDH (glucose dehydrogenase), SOX9, CRY1, CRY2, and SDHA/SDHB, among others.
What diseases are associated with defects in FAD binding?
Defects in FAD binding or FAD homeostasis are linked to Friedreich ataxia, multiple acyl-CoA dehydrogenase deficiency, circadian rhythm disorders, and certain cancers.
How is FAD binding studied experimentally?
Common methods include X-ray crystallography, isothermal titration calorimetry, enzyme activity assays, and CRISPR-based functional screens.
What is the role of FAD in cryptochrome function?
FAD acts as a chromophore in cryptochromes, enabling light-dependent electron transfer that regulates circadian rhythms.
Can FAD supplementation treat genetic diseases?
FAD supplementation has been shown to rescue phenotypes of frataxin deficiency in models of Friedreich ataxia, suggesting therapeutic potential.
What is the difference between FAD and FMN binding?
FAD (flavin adenine dinucleotide) contains an AMP moiety linked to FMN (flavin mononucleotide); FAD binding proteins often bind FAD as a prosthetic group, while FMN is a simpler flavin.
How can CRISPR be used to study FAD binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of FAD-binding genes to assess their function in cells and organisms.
What are the industrial applications of FAD-dependent enzymes?
FAD-dependent glucose dehydrogenase is used in glucose biosensors, and styrene monooxygenase is used in bioremediation.
What is the QuickGO definition of GO:0050660?
The QuickGO definition is: Binding to FAD, flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes, in either the oxidized form, FAD, or the reduced form, FADH2.
Conclusion
GO:0050660 flavin adenine dinucleotide binding is a fundamental molecular function that underpins diverse biological processes, from energy metabolism to circadian regulation. Its dysfunction is implicated in metabolic, neurodegenerative, and infectious diseases. Advances in structural biology and CRISPR-based functional genomics are accelerating our understanding of FAD binding and opening new therapeutic avenues. EDITGENE provides the tools and expertise to interrogate FAD-binding proteins with precision, empowering researchers to translate basic discoveries into clinical impact.
References
- 1. Islam Z et al.. 2022. Flavin Adenine Dinucleotide (FAD) and Pyridoxal 5'-Phosphate (PLP) Bind to Sox9 and Alter the Expression of Key Pancreatic Progenitor Transcription Factors.. Int J Mol Sci 23(22) PMID: 36430529
- 2. Moreno A et al.. 2022. Cofactors and pathogens: Flavin mononucleotide and flavin adenine dinucleotide (FAD) biosynthesis by the FAD synthase from Brucella ovis.. IUBMB Life 74(7):655-671 PMID: 34813144
- 3. Sjulstok E et al.. 2020. Structural Explanations of Flavin Adenine Dinucleotide Binding in Drosophila melanogaster Cryptochrome.. J Phys Chem Lett 11(10):3866-3870 PMID: 32330039
- 4. Gremer L et al.. 2000. Binding of flavin adenine dinucleotide to molybdenum-containing carbon monoxide dehydrogenase from Oligotropha carboxidovorans. Structural and functional analysis of a carbon monoxide dehydrogenase species in which the native flavoprotein has been replaced by its recombinant counterpart produced in Escherichia coli.. J Biol Chem 275(3):1864-72 PMID: 10636886
- 5. Gassner GT. 2019. The styrene monooxygenase system.. Methods Enzymol 620:423-453 PMID: 31072496
- 6. Gonzalez-Cabo P et al.. 2010. Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency.. PLoS One 5(1):e8872 PMID: 20111601
- 7. Mather M et al.. 1982. Studies of the flavin adenine dinucleotide binding region in Escherichia coli pyruvate oxidase.. J Biol Chem 257(21):12887-92 PMID: 6752143
- 8. Lee H et al.. 2020. Biosensing and electrochemical properties of flavin adenine dinucleotide (FAD)-Dependent glucose dehydrogenase (GDH) fused to a gold binding peptide.. Biosens Bioelectron 165:112427 PMID: 32729543
